- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05073458
Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia (PATHWAY)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Salzburg CET, Austria, A-5020
- Investigative Site AT002
-
Vienna, Austria, 01090
- Investigative Site AT001
-
-
-
-
-
La Louviere, Belgium, 07100
- Investigative Site BE001
-
Liege, Belgium, 04000
- Investigative Site BE002
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2P4
- Investigative Site CA001
-
-
-
-
-
Lille Cedex, France, 59037
- Investigative Site FR002
-
Marseille, France, 13285
- Investigative Site FR003
-
Paris, France, 75015
- Investigative Site FR001
-
-
-
-
-
Essen, Germany, 45147
- Investigative Site DE001
-
ULM, Germany, 89081
- Investigative Site DE002
-
-
-
-
-
Haifa, Israel, 31096
- Investigative Site IL002
-
Nahariya, Israel, 2210001
- Investigative Site IL001
-
-
-
-
-
Firenze, Italy, 50134
- Investigative Site IT003
-
Milan, Italy, 20122
- Investigative Site IT002
-
Novara, Italy, 28100
- Investigative Site IT001
-
Pavia, Italy, 27100
- Investigative Site IT004
-
Rome, Italy, 00168
- Investigative Site IT006
-
Trieste, Italy, 34125
- Investigative Site IT005
-
-
-
-
-
Fukuoka, Japan, 807-8556
- Investigative Site JP008
-
Isehara, Japan, 259-1193
- Investigative Site JP004
-
Nagoya, Japan, 467-8602
- Investigative Site JP006
-
Okayama, Japan, 700-8557
- Investigative Site JP009
-
Okayama, Japan, 701-0192
- Investigative Site JP002
-
Osakasayama-shi, Japan, 589-8511
- Investigative Site JP010
-
Saitama, Japan, 350-0495
- Investigative Site JP005
-
Sendai-shi, Japan, 980-8574
- Investigative Site JP007
-
Suita-shi, Japan, 565-0871
- Investigative Site JP001
-
Tokyo, Japan, 141-8625
- Investigative Site JP003
-
-
-
-
-
Rotterdam, Netherlands, 3015CA
- Investigative Site NL001
-
-
-
-
-
Legnica, Poland, 59220
- Investigative Site PL001
-
Lodz, Poland, 93-510
- Investigative Site PL006
-
Nowy Sacz, Poland, 33-300
- Investigative Site PL003
-
Opole, Poland, 45-372
- Investigative Site PL005
-
Walbrzych, Poland, 58-309
- Investigative Site PL004
-
Wroclaw, Poland, 53-439
- Investigative Site PL002
-
-
-
-
-
Badalona, Spain, 08916
- Investigative Site ES006
-
Barcelona, Spain, 08036
- Investigative Site ES001
-
Madrid, Spain, 28006
- Investigative Site ES003
-
Murcia, Spain, 30008
- Investigative Site ES005
-
Tarragona, Spain, 43005
- Investigative Site ES004
-
Valencia, Spain, 46026
- Investigative Site ES002
-
-
-
-
-
Glasgow, United Kingdom, G4 0SF
- Investigative Site GB002
-
London, United Kingdom, W12 0HS
- Investigative Site GB006
-
Norwich, United Kingdom, NR4 7UY
- Investigative Site GB003
-
Plymouth, United Kingdom, PL6 8DH
- Investigative Site GB004
-
Reading, United Kingdom, RG1 5AN
- Investigative Site GB005
-
-
-
-
California
-
Los Angeles, California, United States, 90089
- Investigative Site US005
-
Whittier, California, United States, 90603
- Investigative Site US004
-
-
Florida
-
Miami, Florida, United States, 33165
- Investigative Site US006
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
- Investigative Site US012
-
-
New York
-
Bronx, New York, United States, 10461
- Investigative Site US007
-
Bronx, New York, United States, 10467
- Investigative Site US002
-
-
North Carolina
-
Greenville, North Carolina, United States, 27858
- Investigative Site US003
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Investigative Site US009
-
-
Pennsylvania
-
Easton, Pennsylvania, United States, 18045
- Investigative Site US010
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37920
- Investigative Site US001
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of primary warm AIHA.
- Participants who have at least 1 unsuccessful prior therapy for warm AIHA or unable to receive or tolerate other therapies.
- Hemoglobin ≥ 6.5 to < 10 g/dL with symptoms of anemia at screening.
- FACIT-F score ≤ 43 at screening.
- Willingness to avoid pregnancy or fathering children.
- Willingness to receive PJP prophylaxis.
- Further inclusion criteria apply.
Exclusion Criteria:
- Women who are pregnant, breastfeeding or who are planning a pregnancy.
- Diagnosis of other types of AIHA (CAD, cold agglutinin syndrome, mixed-type AIHA or paroxysmal cold hemoglobinuria).
- Secondary warm AIHA from any cause or diagnosis of Evans syndrome.
- Splenectomy less than 3 months before randomization.
- Participants with a history or ongoing significant illness as assessed by the investigator.
- Participants with a current of medical history of a malignancy within the past 5 years except basal or squamous cell skin cancer that has been removed and considered cured, or superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy.
- Participants know to be infected with HIV, Hepatitis B, or hepatitis C.
- Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment or exposure to a live vaccine.
- Participants with laboratory values outside of the protocol defined ranges.
- Further exclusion criteria apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A: Parsaclisib
Participants will receive parsaclisib for 24 weeks (double-blind period).
Participant who completed the double-blind period and tolerating the study treatment upon investigator's opinion will continue into open-label period for an additional 24 weeks.
Participants may then continue to receive parsaclisib in a long-term extension period.
|
parsaclisib will be administered QD orally
Other Names:
|
Placebo Comparator: Group B: Placebo followed by Parsaclisib
Participants will receive placebo for 24 weeks (double-blind period).
Participants who completed the double-blind period will receive parsaclisib in the 24 week open-label period.
Participants may then continue to receive parsaclisib in a long-term extension period.
|
placebo will be administered QD orally follwed by Parsaclisinib in the open label period
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants attaining a durable hemoglobin response
Time Frame: Up to Week 24
|
Proportion of participants attaining a durable hemoglobin response, defined as hemoglobin ≥ 10 g/dL with an increase from baseline of ≥ 2 g/dL not attributed to rescue therapy at ≥ 3 of the 4 available visits at Week 12 and/or later during the 24-week double-blind treatment period.
|
Up to Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants with a ≥ 3-point increase in FACIT-F score
Time Frame: Up to Week 24
|
Increase is measured by Functional Assessment of Chronic Illness Therapy - Fatigue questionnaire.
The FACIT-F is a 13-item measure that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days.
|
Up to Week 24
|
Proportion of participants with a 50 m increase in a 6MWT
Time Frame: Up to Week 24
|
Defined as an increase of 50 m using the Six-minute walk test, a self-paced measurement of the distance that a participant can quickly walk on a flat, hard surface in a period of 6 minutes.
|
Up to Week 24
|
Change in FACIT-F score
Time Frame: Up to 3 years
|
Change will be measured by Functional Assessment of Chronic Illness Therapy - Fatigue questionnaire.
The FACIT-F is a 13-item measure that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days.
|
Up to 3 years
|
Percent Change in FACIT-F
Time Frame: Up to 3 years
|
will be measured by Functional Assessment of Chronic Illness Therapy - Fatigue questionnaire.
The FACIT-F is a 13-item measure that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days.
|
Up to 3 years
|
Change in hemoglobin
Time Frame: Up to 3 years
|
Changes will be measured and compared in the hematology panel.
|
Up to 3 years
|
Percentage change in hemoglobin
Time Frame: Up to 3 years
|
Percentage change will be measured and compared in the hematology panel.
|
Up to 3 years
|
Proportion of participants who received transfusions
Time Frame: Up to 48 weeks
|
Proportion of participants who received transfusions.
|
Up to 48 weeks
|
Change in corticosteroid dose from baseline
Time Frame: Up to Week 24
|
Change from baseline of daily corticosteroids dose
|
Up to Week 24
|
Percentage change from baseline in daily corticosteroid dose
Time Frame: Up to Week 24
|
Percentage change from baseline of daily corticosteroids dose
|
Up to Week 24
|
Proportion of participants who required rescue therapy at any visit
Time Frame: Up to 48 weeks
|
Rescue therapy will include new/increased dose of corticosteroids, transfusions, intravenous immunoglobulin (IVIG), and Erythropoietin.
|
Up to 48 weeks
|
Number of Participants with Treatment Emergent Adverse Events (TEAE)
Time Frame: Up to 3 years
|
Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug.
|
Up to 3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Kathleen Butler, MD, Incyte Corporation
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- INCB 50465-309
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Warm Autoimmune Hemolytic Anemia (wAIHA)
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
-
Novartis PharmaceuticalsRecruitingWarm Autoimmune Hemolytic Anemia (wAIHA)China, Japan, Spain, Singapore, France, Germany, Taiwan, United States, Italy, India, Malaysia, Argentina, Hungary, Israel, Australia, Thailand, United Kingdom, Romania
-
Annexon, Inc.CompletedWarm Autoimmune Hemolytic Anemia (wAIHA)United States
-
Eugene NikitinUnknownAIHA - Warm Autoimmune Hemolytic AnemiaRussian Federation
-
Bioverativ, a Sanofi companyAssign Data Management and Biostatistics GmbH; Quest Diagnostics-Nichols Insitute and other collaboratorsCompletedEnd-stage Renal Disease (ESRD) | Cold Agglutinin Disease (CAD) | Bullous Pemphigoid (BP) | Warm Autoimmune Hemolytic Anemia (WAIHA)Austria
-
Peking Union Medical College HospitalRecruiting
-
Alexion PharmaceuticalsWithdrawnWarm Autoimmune Hemolytic AnemiaUnited States
-
Alexion PharmaceuticalsTerminatedWarm Autoimmune Hemolytic AnemiaUnited States, Jordan
-
Chen MiaoNot yet recruiting